ALNY241220C230000
- 24.80
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $304
The Nasdaq 100 is about to adjust, and these 11 companies may see a 50% increase in upside potential.
As the annual adjustment of the NASDAQ 100 Index approaches, a group of potential stocks is preparing to make their debut. This adjustment not only brings prestige to these companies but may also trigger a large-scale inflow of capital, further driving up stock prices.
Alnylam Pharmaceuticals Insider Sold Shares Worth $439,760, According to a Recent SEC Filing
Palantir, MicroStrategy Could Be Added to Nasdaq 100 Friday. Moderna, Super Micro Could Be Dropped.
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
MicroStrategy Stock Could Get Added to the Nasdaq 100 Because of a Quirk
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $296
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now?
Don't Ignore The Insider Selling In Alnylam Pharmaceuticals
Alnylam Pharmaceuticals: Promising Advancements in Alzheimer's Treatment With RNA Interference Therapeutics
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Announces Target Price $272
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
FDA Begins Review of Alnylam's SNDA for Expanded Amvuttra Use
Scotiabank Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $384